ReviewCancers2019
Circulating microRNAs as Promising Biomarkers in Colorectal Cancer.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- mirSNPs as Potential Colorectal Cancer Biomarkers: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.Bioscience reports · 2020Pooled it
- Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers.International journal of molecular sciences · 2020Pooled it
- Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies.International journal of molecular sciences · 2019Pooled it
- Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Review
- The role of UGT1A1 polymorphism in the management of colorectal cancer.Oncology reviews · 2025Review
- Liquid Biopsy and Colorectal Cancer.South Asian journal of cancer · 2024Review
- Acoustic separation and concentration of exosomes for nucleotide detection: ASCENDx.Science advances · 2024Article
- Surface-Enhanced Raman Spectroscopy-Based Detection of Micro-RNA Biomarkers for Biomedical Diagnosis Using a Comparative Study of Interpretable Machine Learning Algorithms.Applied spectroscopy · 2024Article
- Novel insights on perils and promises of miRNA in understanding colon cancer metastasis and progression.Medical oncology (Northwood, London, England) · 2023Review
- Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.International journal of molecular sciences · 2023Review
- Targeting miR-5088-5p attenuates radioresistance by suppressing Slug.Non-coding RNA research · 2023Article
- Review
- Review
- miRNA probe integrated biosensor platform using bimetallic nanostars for amplification-free multiplexed detection of circulating colorectal cancer biomarkers in clinical samples.Biosensors & bioelectronics · 2023Article
- Circulating microRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application.The Journal of pharmacology and experimental therapeutics · 2023Review
- Exploring the interplay betweenFrontiers in microbiology · 2023Article
- Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: A systematic review and meta-analysis.Frontiers in surgery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer-related deaths worldwide. Despite numerous advances in therapeutic approaches, this cancer has a poor prognosis when it is diagnosed at late stages. Therefore, the scientific effort is nowadays directed towards the development of new non-invasive and dynamic biomarkers to improve the survival expectancy of CRC patients. In this sense, deregulated expression of many miRNAs has been shown to play an important role for CRC carcinogenesis and dissemination. Noticeably, an increasing number of studies highlight that circulating miRNAs, including those traveling inside exosomes or those released by tumor cells into circulation, constitute a promising tool for early detection, prognosis and therapy selection of CRC. Therefore, in this review we focus on the clinical potential of blood circulating miRNAs as emerging biomarkers with high value to improve the clinical management of CRC patients, providing a deep and complete perspective of the realities and challenges to translate these biomarkers to the clinical context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.